Project

RRM2 controlled replicative stress resistance as a druggable DNA copy number driven cell state in MYC(N) driven cancers

Duration
01 October 2016 → 30 September 2020
Funding
Research Foundation - Flanders (FWO)
Research disciplines
  • Natural sciences
    • Genetics
    • Systems biology
  • Medical and health sciences
    • Laboratory medicine
    • Medical systems biology
    • Molecular and cell biology
    • Laboratory medicine
    • Medical systems biology
    • Molecular and cell biology
    • Laboratory medicine
    • Medical systems biology
    • Molecular and cell biology
Keywords
RRM2 replicative stress resistance MYCN
 
Project description

The MYCN oncogene plays a central role in neuroblastoma development, with high expression inferring a poor prognosis. The MYCN regulatory network has been shown to serve as a promising drug target. In this project, I will study the novel candidate oncogene RRM2, which enables a replicative stress resistance phenotype in MYCN driven tumors, using in vivo and in vitro assays.